A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
NiKang Therapeutics, Inc.
NiKang Therapeutics, Inc.
Dartmouth-Hitchcock Medical Center
Universitaire Ziekenhuizen KU Leuven
Rain Oncology Inc
Rain Oncology Inc
University Hospital of North Norway
Leiden University Medical Center
Institute of Cancer Research, United Kingdom
Maastricht Radiation Oncology
Maastricht Radiation Oncology
Maastricht Radiation Oncology
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
BioMed Valley Discoveries, Inc
Radboud University Medical Center